Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer
Go back to Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer| (NASDAQ: PPCB) | Delayed: 0.27 -0.05 (15.63%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.32 | 52 Week High | $ | |||
| Open | $0.29 | 52 Week Low | $ | |||
| Day High | $0.30 | P/E | N/A | |||
| Day Low | $0.27 | EPS | $ | |||
| Volume | 213,246 | |||||
| (NASDAQ: PPCB) | Delayed: 0.27 -0.05 (15.63%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.32 | 52 Week High | $ | |||
| Open | $0.29 | 52 Week Low | $ | |||
| Day High | $0.30 | P/E | N/A | |||
| Day Low | $0.27 | EPS | $ | |||
| Volume | 213,246 | |||||



